Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.
Richard Moldawsky, MD.Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Medications don’t have a good track record in PTSD, particularly in combat related trauma. Here we review two controlled trials where an old standby (mirtazapine) and a hopeful contender (riluzole) come up short.
Kristen Gardner, PharmD.Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
More is not necessarily better in psychopharmacology. Some medications have plateau effect, while others follow a “U-shaped curve,” causing more problems as the dose goes too high. This metaanalysis looked at 77 dose-response trials with antidepressants to quantify their optimal therapeutic window.
When a popular antidepressant combination is discredited, what do we do with it? Dr. Aiken sorts through the possibilities for mirtazapine (Remeron) augmentation, and pulls up a few more myths about this medicine.Date Published: 9/23/19Duration: 9 minutes 11 secondsArticle Referenced: "Mirtazapine Augmentation: Running Low on Rocket Fuel," The Carlat Psychiatry...
Thomas Jordan, MD and Chris Aiken, MD.Dr. Jordan and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Dubbed “California Rocket Fuel” by Stephen Stahl, the combination of venlafaxine and mirtazapine seemed to hit all the right receptors. The hype may have gotten a little ahead of the evidence on this one, however, as three new studies reveal.